Research programme: ER stress response modulators - Aravive BiologicsAlternative Names: 2-series; 4-series ER stress
Latest Information Update: 06 Dec 2016
At a glance
- Originator Ruga Corporation
- Developer Aravive Biologics
- Mechanism of Action Cell physiology modulators; Protein folding modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Multiple myeloma
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Multiple-myeloma in USA
- 22 May 2012 Early research in Multiple myeloma in USA (unspecified route)